6R
6RC.F ReproCELL Incorporated
- Market cap
- EUR 54.4M
- P/E
- -
- P/B
- 1.02x
- ROE
- -6.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is 6RC.F undervalued?
Graham numberThe Graham number of ReproCELL Incorporated cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ReproCELL Incorporated fundamental analysis
No fundamental analysis for ReproCELL Incorporated yet.
ReproCELL Incorporated stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ReproCELL Incorporated
ReproCELL Incorporated provides stem cell research and drug discovery services in Japan. It offers stem cell reagents, including RNA reprogramming, small molecules, growth factors and cytokines, antibodies and staining kits, cell substrates, cryopreservation media, dissociation solution, and transfection reagents; differentiated induced pluripotent stem cell (iPSC) and related reagents, feeder cells, pluripotent stem cells, StemEdit gene edited iPSCs, mesenchymal stem cells …
Full company profileReproCELL Incorporated financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ReproCELL Incorporated annual financial statements (JPY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.26B | 926M | 1.09B | 1.20B | 1.29B | 2.23B | 2.95B | 2.43B | 2.98B | 2.23B | 2.19B |
| Gross Profit | 576M | 381M | 496M | 475M | 483M | 803M | 1.14B | 1.12B | 1.65B | 1.02B | 980M |
| Operating Income | -944M | -1.03B | -781M | -909M | -1.05B | -647M | -356M | -409M | -130M | -860M | -1.24B |
| EBITDA | - | -2.03B | -574M | -949M | -750M | -514M | -255M | -372M | -79.7M | -785M | -1.24B |
| Net Income | -912M | -2.17B | -601M | -1.02B | -813M | -575M | -305M | -31.4M | 103M | -592M | -598M |
| EPS | -15 | -34 | -8.46 | -14 | -11 | -6.99 | -3.59 | -0.35 | 1.09 | -6.23 | -6.10 |
| Balance Sheet | |||||||||||
| Total Assets | 7.85B | 6.60B | 7.49B | 6.55B | 6.05B | 8.10B | 8.36B | 9.05B | 9.67B | 9.05B | 9.80B |
| Total Liabilities | 486M | 349M | 419M | 495M | 656M | 845M | 781M | 741M | 686M | 741M | 728M |
| Shareholders' Equity | 7.37B | 6.25B | 7.07B | 6.05B | 5.38B | 7.25B | 7.58B | 8.31B | 8.98B | 8.31B | 9.07B |
| Cash & Short-term Investments | 3.41B | 3.57B | 4.11B | 4.59B | 2.60B | 2.64B | 1.91B | 2.94B | 2.82B | 2.94B | 2.00B |
| Cash Flow | |||||||||||
| Operating Cash Flow | -775M | -636M | -554M | -689M | -648M | -246M | -141M | -11.5M | 6.29M | -384M | - |
| Capital Expenditure | 65.0M | 43.0M | 91.0M | 120M | 60.0M | 44.0M | 161M | 192M | 96.1M | 98.2M | 0.00 |
| Free Cash Flow | - | -680M | -652M | -831M | -713M | -294M | -302M | -204M | -89.9M | -482M | - |
| Ratios | |||||||||||
| ROE | -12.4% | -34.8% | -8.5% | -16.8% | -15.1% | -7.9% | -4.0% | -0.4% | 1.1% | -7.1% | -6.6% |
| ROA | -11.6% | -32.9% | -8.0% | -15.5% | -13.4% | -7.1% | -3.7% | -0.3% | 1.1% | -6.5% | -6.1% |
| Net Profit Margin | -72.5% | -234.5% | -55.3% | -84.7% | -63.2% | -25.7% | -10.3% | -1.3% | 3.5% | -26.5% | -27.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ReproCELL Incorporated dividends
ReproCELL Incorporated has not paid dividends in the last 9 fiscal years.
Last stock split: 5:1 on Aug 28, 2013.
Who owns ReproCELL Incorporated
- Insiders 5.86%
- Institutions 6.31%
- Public & others 87.82%
- Shares outstanding 98.0M
- Free float 90.7M
ReproCELL Incorporated company profile
- Company name
- ReproCELL Incorporated
- Ticker
- 6RC.F
- ISIN
- JP3974770004
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 101
- Fiscal year end
- March
- Address
- MetLife Shin-Yokohama Building, Yokohama, Japan, 222-0033
- Phone
- 81 45 475 3887
- Website
- reprocell.com
About ReproCELL Incorporated
ReproCELL Incorporated provides stem cell research and drug discovery services in Japan. It offers stem cell reagents, including RNA reprogramming, small molecules, growth factors and cytokines, antibodies and staining kits, cell substrates, cryopreservation media, dissociation solution, and transfection reagents; differentiated induced pluripotent stem cell (iPSC) and related reagents, feeder cells, pluripotent stem cells, StemEdit gene edited iPSCs, mesenchymal stem cells (MSCs), and new immortalized cell lines and related reagents; and iPSC-derived exosomes. The company also provides Alvetex 3D, a cell culture system; Alvetex, an advanced tissue bioengineering system; EZSPHERE Multiwell Dishes and Plates; KOKEN atelocollagen; ABLE Biott bioreactor systems; and 2mag stirrer systems. In addition, It offers research stem cell, genomics, clinical stem cell research, preclinical and drug discovery, precision medicine, human tissue samples, clinical laboratory, and gene editing services. ReproCELL Incorporated was incorporated in 2003 and is based in Yokohama, Japan.
ReproCELL Incorporated management
10- Dr. Chikafumi Yokoyama Ph.D.CEO, President & Representative Director · born 1968
- Assist. Prof. Taeko Naruse Ph.D.Founders & Adviser
- Mr. Hiroyuki Mizuguchi Ph.D.Advisor & Founder
- Mr. Wado Akamatsu M.D., Ph.D.Founders & Adviser
- Mr. Hiroshi Yagi M.D., Ph.D.Advisor & Founder
- Satoshi MunemuraCFO & GM of Business Administration Dept.
- Mr. Daisuke UsuiCOO & Director · born 1973
- Prof. Stefan A. Przyborski BSc Ph.D.CSO of REPROCELL Europe Ltd.
- Mr. Ramakrishna V. ModaliChief Executive Officer of REPROCELL USA Inc.
- Dr. David Bunton Ph.D.Chief Executive officer of REPROCELL Europe